-
EBMT 2026 China Voice | Professor Yuqian Sun: A New Strategy for Donor Selection in Elderly Haploidentical Transplantation — Younger Donors Are Better
The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from March 22 to 25, 2026, in Madrid, Spain. As one of the most influential academic events in the field, the congress brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
-
ASCO GU Expert Insights | Professor Scott T. Tagawa: Transforming Prostate Cancer Care and the Future of Precision Therapy
he 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) marked a pivotal moment in prostate cancer research, featuring updates in disease classification, major clinical trial readouts, and evolving treatment paradigms.
-
EBMT 2026 Highlights | Restoring T-cell Fitness and Enhancing CAR-T Expansion in Bendamustine-Exposed R/R B-NHL
The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from March 22 to 25, 2026, in Madrid, Spain. As one of the most influential international conferences in hematology, EBMT brings together experts worldwide to discuss cutting-edge advances in hematopoietic stem cell transplantation and cellular therapy.
-
EBMT 2026 China Voice | Professor Xing-Yu Cao: Sequential CD7 CAR-T Followed by Second Transplant Improves Survival to Nearly 50% in Post-Transplant Relapsed T-ALL/LBL
Patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) who relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have an extremely poor prognosis. Historically, treatment options have been limited, and even with a second transplant, long-term survival has remained below 30%. There is therefore an urgent need for more effective therapeutic strategies.
-
EBMT 2026 China Voice | Professor Heng Mei: Exploring the Global Frontiers of Cellular Therapy—From In Vivo CAR-T to Technological Innovation
At the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2026), held in Madrid, “Cell Therapy Day” emerged as one of the most prominent highlights of the congress. The session brought together leading experts from China, the United States, Germany, and other countries, who shared cutting-edge advances and forward-looking perspectives…
-
EBMT 2026 China Voice | Professor Xiao-Xia Hu: Refining Risk Stratification and Optimizing Decision-Making—Fusion Gene–Guided Transplant Strategies in CBF-AML
From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain, bringing together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy. Key topics included optimization of transplant strategies, infection control, CAR-T therapy, and graft-versus-host disease…
-
ASCO GU China Voice | Professor Hai-Long Hu’s Team: The TRUCE Program Advances Comprehensive Management of Urothelial Carcinoma with New Evidence from China
The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded, delivering multiple landmark advances that are reshaping clinical practice in urologic oncology.
-
ASCO GU China Voice | Professor Hao Zeng: Five Key Studies from West China Hospital Unlock New Directions for Difficult-to-Treat and Special Populations in Urologic Oncology
The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) brought together cutting-edge advances and landmark studies in genitourinary oncology from around the world.
Connecting Medical Expertise through Media